Patents Assigned to UCB Pharma S.A.
  • Patent number: 10189897
    Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: January 29, 2019
    Assignee: UCB PHARMA, S.A.
    Inventors: Mariangela Spitali, Jonathan Symmons, Richard Whitcombe, Mark Robert Pearce-Higgins
  • Patent number: 10017575
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: July 10, 2018
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Publication number: 20180169235
    Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
    Type: Application
    Filed: February 2, 2018
    Publication date: June 21, 2018
    Applicant: UCB PHARMA, S.A.
    Inventor: Martyn K. Robinson
  • Patent number: 9957328
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 1, 2018
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9925260
    Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 27, 2018
    Assignee: UCB PHARMA S.A.
    Inventor: Martyn Kim Robinson
  • Patent number: 9828438
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: November 28, 2017
    Assignee: UCB Pharma S.A.
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Publication number: 20170306052
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 26, 2017
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Patent number: 9791462
    Abstract: A novel class or family of TGF-? binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 17, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mary E. Brunkow, David J. Galas, Brian Kovacevich, John T. Mulligan, Bryan W. Paeper, Jeffrey Van Ness, David G. Winkler
  • Patent number: 9751930
    Abstract: The present invention provides method for purifying a recombinant protein from a gram-negative bacterial host cell sample or extract thereof wherein said host cell expresses a recombinant protein and a recombinant disulphide isomerase DsbC; comprising: a. adjusting the pH of the host cell sample or extract thereof to a pH of 5 or less to precipitate the recombinant disulphide isomerase; and b. separating precipitated recombinant disulphide isomerase DsbC from the recombinant protein to produce a recombinant protein sample.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: September 5, 2017
    Assignee: UCB PHARMA, S.A.
    Inventor: Gavin Barry Wild
  • Patent number: 9725516
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 8, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Publication number: 20170182159
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: March 6, 2017
    Publication date: June 29, 2017
    Applicant: UCB Pharma S.A.
    Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
  • Patent number: 9657095
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: May 23, 2017
    Assignee: UCB PHARMA S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Patent number: 9630948
    Abstract: The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: April 25, 2017
    Assignee: UCB Pharma, S.A.
    Inventors: Florian Montel, Eric Jnoff
  • Patent number: 9631015
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: April 25, 2017
    Assignee: UCB Pharma S.A.
    Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
  • Patent number: 9587227
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 7, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9550973
    Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: January 24, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9493558
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a mutant spr protein and wherein the cell comprises a non-recombinant wild-type chromosomal Tsp gene.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 15, 2016
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9493559
    Abstract: The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 15, 2016
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9428570
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: August 30, 2016
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Patent number: 9399671
    Abstract: The invention relates to a transcriptionally active recombinant linear polynucleotide encoding a multimeric protein comprising in the following order, a first promoter sequence, a first encoding polynucleotide sequence, a bidirectional regulatory sequence, a second encoding polynucleotide sequence and a second promoter sequence, wherein the first and second encoding polynucleotide sequences are in convergent transcriptional orientation, each encoding polynucleotide sequence encodes a component of the multimeric protein and the bidirectional regulatory sequence is operably linked to the first and second encoding polynucleotide sequences and the multimeric protein is an antibody or fragment thereof and each encoding polynucleotide sequence encodes one or more antibody domains or fragments thereof.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: July 26, 2016
    Assignee: UCB PHARMA S.A.
    Inventors: Mark Ellis, Laura Ellen Newnham